Insect Immunity
ISOLATION FROM THE LEPIDOPTERAN HELIOTHIS VIRESCENS OF A NOVEL INSECT DEFENSIN WITH POTENT ANTIFUNGAL ACTIVITY*

Mireille LambertyDagger , Sarah AdesDagger , Sandrine Uttenweiler-JosephDagger , Gary Brookhart§, Dean Bushey§, Jules A. HoffmannDagger , and Philippe BuletDagger

From the Dagger  Institut de Biologie Moléculaire et Cellulaire, Unité Propre de Recherche 9022, CNRS, "Réponse Immunitaire et Développement chez les Insectes," 15 rue René Descartes, 67084 Strasbourg Cedex, France and § Rhône-Poulenc Agro, Research Triangle Park, North Carolina 27709-2014

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Lepidoptera have been reported to produce several antibacterial peptides in response to septic injury. However, in marked contrast to other insect groups, no inducible antifungal molecules had been described so far in this insect order. Surprisingly, also cysteine-rich antimicrobial peptides, which predominate in the antimicrobial defense of other insects, had not been discovered in Lepidoptera. Here we report the isolation from the hemolymph of immune induced larvae of the lepidopteran Heliothis virescens of a cysteine-rich molecule with exclusive antifungal activity. We have fully characterized this antifungal molecule, which has significant homology with the insect defensins, a large family of antibacterial peptides directed against Gram-positive strains. Interestingly, the novel peptide shows also similarities with the antifungal peptide drosomycin from Drosophila.

Thus, Lepidoptera appear to have built their humoral immune response against bacteria on cecropins and attacins. In addition, we report that Lepidoptera have conferred antifungal properties to the well conserved structure of antibacterial insect defensins through amino acid replacements.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cotton is grown in more than 60 countries and plays a major role in the economy of these countries. The demand for cotton has not fallen despite the rapid growth in synthetic fiber production since 1960. The major biotic yield constraints are animal pests and weeds, although in all growing regions there are also diseases causing losses of cotton yields. Cotton plants appear to have little inherent defense against attack by insect pests. In fact, many insect species have been reported on cotton, and some of these species are regarded as major pests that can destroy the plants in a few days. In most growing regions, the principal pests are larvae of lepidopteran species that attack the roots, leaves, flowers, and bolls. This is in particular the case for the following species: Pectinophora gossypiella (pink bollworm), Heliothis armigera (American bollworm), H. virescens (tobacco budworm), and Earias spp. (spiny bollworm). Each year, these species cost the cotton industry millions of dollars in yield loss and control measures (1). In this context, the knowledge of the immune response mechanisms of the lepidopteran larvae is of great interest. Indeed, these mechanisms can represent a potential target for controlling these pests. In the present study, we have chosen H. virescens as a biological model.

The host defense of insects relies on cellular and humoral mechanisms. The cellular response consists of phagocytosis and encapsulation of invading microorganisms by blood cells (for a review, see Ref. 2). The humoral facet of the defense reactions of insects has been extensively studied, and it is now clear that it is essentially based on the synthesis of a battery of cationic antibacterial and antifungal peptides/polypeptides exhibiting broad activity spectra. These antimicrobial molecules are produced in the fat body (a functional equivalent of the mammalian liver) and released into the hemolymph (blood). Today, more than 150 antimicrobial peptides have been characterized from various insect species. Although they exhibit great structural diversities, certain common structural patterns are apparent, and the peptides are often grouped into four families: (i) cecropins, (ii) cysteine-rich peptides, (iii) proline-rich peptides, and (iv) glycine-rich peptides/polypeptides (for reviews, see Refs. 2-4). Cecropins, which were the first inducible antibacterial peptides to be characterized (5), are linear 4-kDa cationic peptides isolated from Lepidoptera and Diptera. They are devoid of cysteine residues and consist of two alpha -helices linked by a short hinge (for a review, see Ref. 6). Cecropins are frequently C-terminally amidated. They kill Gram-positive and Gram-negative bacteria. The group of cysteine-rich peptides contains members with 1-4 disulfide bridges with molecular masses ranging from 2 to 6 kDa. The most widespread of insect antimicrobial compounds, the insect defensins, belong to this group. They contain six cysteine residues involved in three disulfide bridges (7). Defensins are active against Gram-positive bacteria. Their presence has been reported from many insect orders and also from scorpions and molluscs (8, 9). Hitherto, they had not been isolated from Lepidoptera. In addition to these antibacterial cysteine-rich peptides, two cysteine-containing peptides with antifungal activity have been characterized so far from insects: drosomycin from the dipteran Drosophila melanogaster (10) and thanatin from the hemipteran Podisus maculiventris (11). In response to septic injury, larvae and adults of Drosophila produce considerable amounts of drosomycin, a 5-kDa peptide with eight cysteine residues that are engaged in the formation of four intramolecular disulfide bridges. Drosomycin is inactive against bacteria. It shows significant homology with plant defensins, e.g. Rs-AFP2 from Raphanus sativus (10). Thanatin is a 2-kDa peptide exhibiting both fungicidal and bactericidal activities. The third group of antimicrobial peptides from insects, the proline-rich molecules, have been isolated from Hymenoptera, Diptera, Lepidoptera, and Hemiptera (for a review, see Ref. 3). They are active against Gram-negative bacteria, and for some members of this group activity against Gram-positive bacteria and fungi was also reported. Some of the proline-rich peptides are O-glycosylated (e.g. drosocin (12)). Finally, the glycine-rich peptides/polypeptides, which are mostly large (8-24 kDa), are active against Gram-negative cells. They include attacins, characterized in Lepidoptera and Diptera (13); sarcotoxins II (14); and diptericins from Diptera (15, 16).

As regards the order of Lepidoptera, to which belongs H. virescens, a number of inducible antibacterial peptides had already been isolated when we engaged in the present study. These include, in addition to the cecropins and attacins mentioned above, gloverin (17), moricin (18), and lebocins (19). Gloverin is a 14-kDa inducible cationic antibacterial polypeptide isolated from pupae of the giant silk moth Hyalophora cecropia. It contains a large number of glycine residues but is devoid of cysteine residue. Moricin is a 4-kDa antibacterial peptide isolated from Bombyx mori. Neither moricin nor gloverin range into any of the four groups of antimicrobial peptides/polypeptides defined above. Finally, lebocins that were isolated from hemolymph of immunized B. mori are structurally related to proline-rich peptides. Interestingly, the unique threonine residue in each lebocin is O-glycosylated.

From H. virescens, our experimental model, the presence of cecropin-like and attacin-like molecules has been described, but no amino acid sequences have been published (20, 21). Intriguingly, no cysteine-rich peptides have been reported so far from Lepidoptera, and no antifungal activities have been recorded from this order.

We present here the isolation of a novel inducible antifungal peptide, the structure of which shares similarities with insect defensins, with the Drosophila antifungal peptide drosomycin, and with antifungal plant defensins.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Insect Immunization and Hemolymph Collection

Fifth instar larvae of the lepidopteran H. virescens were individually pricked with a 30-gauge needle dipped into a combined bacterial pellet obtained after centrifugation of 37 °C overnight cultures of Micrococcus luteus and Escherichia coli 1106. After 24 h, the insects were chilled on a bed of ice, and several drops (30 µl/larva) of hemolymph were recovered by sectioning an abdominal appendix and gently squeezing the abdomen. The hemolymph was pooled in ice-cold polypropylene tubes containing aprotinin as a protease inhibitor (20 µg/ml final concentration) and phenylthiourea as a melanization inhibitor (20 µM final concentration). After a centrifugation at 14,000 × g for 1 min at 4 °C, the cell-free hemolymph was frozen at -20 °C until use. In a control experiment, a hemolymph sample from unchallenged H. virescens larvae was processed in the same manner.

Purification Procedure

Sep-Pak Prepurification Two ml of cell-free hemolymph, from untreated or bacteria-challenged larvae, were acidified to pH 3 with 0.1% (v/v) trifluoroacetic acid. The acidic extraction was performed for 30 min under gentle shaking in an ice-cold water bath. After centrifugation (10,000 × g for 30 min at 4 °C), the supernatant was loaded onto Sep-Pak C18 cartridges (Waters) equilibrated with acidified water (0.05% trifluoroacetic acid). Elutions were performed with 10, 40, and 100% acetonitrile in acidified water. All fractions were first concentrated in a vacuum centrifuge (Speed-Vac, Savant) in order to remove the organic solvent and trifluoroacetic acid and subsequently reconstituted with MilliQ water.

First Step of Purification The two 40% Sep-Pak fractions from immunized and control insects were purified in parallel by reversed-phase HPLC1 on a semipreparative Aquapore RP-300 C8 column (250 × 7.0 mm, Brownlee) equilibrated with 2% acetonitrile in acidified water. Elution was performed with a linear gradient of 2 to 60% acetonitrile in acidified water over 120 min at a flow rate of 1.5 ml/min.

Second Step of Purification The fraction with antifungal activity was applied on an analytical Aquapore OD-300 C18 column (220 × 4.6 mm, Brownlee) developed with a linear biphasic gradient of acetonitrile in acidified water from 2 to 22% over 10 min and from 22 to 32% over 50 min at a flow rate of 0.8 ml/min.

Final Step of Purification The fraction that contained the antifungal activity was further applied on a narrow bore reversed-phase column (Delta Pak HPIC18, 2 × 150 mm, Waters) equilibrated with 2% acetonitrile in acidified water and developed with a linear biphasic gradient of acetonitrile in acidified water from 2 to 24% over 10 min and from 24 to 44% over 100 min at a flow rate of 0.25 ml/min and at a temperature of 30 °C.

The first and second steps of HPLC purification were performed with a Beckman Gold HPLC system equipped with a Beckman 168 photodiode array detector. The last step of purification was carried out at a temperature of 30 °C using an all PEEK Waters HPLC system (Waters model 626 pump) attached to a tunable absorbance detector (Waters model 486) and equipped with an oven. During the purification procedure, the internal diameter of the column was chosen according to the amount of peptide to be purified, while the modification of the gradient was necessary to increase peptide separation.

In all HPLC purification steps, the column effluent was monitored by absorbance at 225 nm to have the most appropriate signal/noise ratio. Fractions were hand-collected in order to have one individual peak per fraction. The presence of antimicrobial activity was detected using liquid growth inhibition assays under the conditions described below.

Bioassays

Microorganisms

Bacterial Strains-- The following are the bacterial strains used with their source (gifts from colleagues): M. luteus A270 from the Pasteur Institut Collection (Paris) and E. coli SBS363 and E. coli 1106 from P. L. Boquet (Center d'Etudes Nucléaires, Saclay).

Fungi and Yeast Strains-- The filamentous fungi and the yeast strains used in this study were generous gifts from different colleagues: Aspergillus fumigatus (H. Koenig, Laboratoire de Mycologie, Faculté de Médecine, Strasbourg, France), Fusarium culmorum (IMI 180420), Fusarium oxysporum (MUCL 909), Nectria hematococca (Collection Van Etten 160-2-2), Neurospora crassa (CBS 327-54), Trichoderma viride (MUCL 19724) (Université Catholique de Leuven, Belgique), Candida albicans, Candida glabrata, Cryptococcus neoformans (H. Koenig, Laboratoire de Mycologie, Faculté de Médecine, Strasbourg, France), and Saccharomyces cerevisiae (Société Transgène, Strasbourg, France).

Antibacterial Assay During the various steps of purification, antibacterial activity was monitored by a liquid growth inhibition assay on the Gram-positive strain M. luteus and on the Gram-negative strain E. coli 363. Ninety µl of a suspension of a midlogarithmic phase culture of bacteria at a starting A600 = 0.001 in Poor Broth nutrient medium (1% Bacto-Tryptone and 0.5% (w/v) NaCl, pH 7.5) were added to 10 µl of fraction to analyze. Microbial growth was assessed by an increase in A600 after a 24-h incubation at 30 °C using a microtitration plate reader.

Antifungal Assays and Determination of the Minimal Inhibitory Concentration Fungal spores (final concentration 104 spores/ml) were suspended in 1/2 Potato Dextrose Broth (Difco), and the yeast strains were suspended at a starting A600 = 0.001 in the yeast complete medium YPG (1% yeast extract, 1% peptone, 2% glucose). The medium was supplemented with tetracyclin (10 mg/ml) and cefotaxim (100 µg/ml), dispensed by aliquots of 80 µl into wells of a microplate containing 20 µl of either water or the fraction to be analyzed. Growth of fungi and yeast was evaluated after 24 h at 30 °C by optical microscopy and after 48 h by measuring the culture absorbance at 595 nm using a microplate reader.

In the conditions where the antifungal assay was performed in the presence of salt, the 1/2 Potato Dextrose Broth medium was prepared in phosphate-buffered saline, 137 mM NaCl.

The procedure used for the determination of the minimal inhibitory concentration (MIC) was identical to that for the antifungal assay. The MIC values are expressed as an interval (a-b), where a is the highest peptide concentration tested at which fungi or yeast are still growing and b is the lowest concentration that causes 100% growth inhibition.

Fungicidal Assay Spores of N. crassa were cultured in the presence of 0.04-20 µM peptide. After 48 h, the 1/2 Potato Dextrose Broth medium containing the peptide was removed and replaced by fresh medium. Two days later, the cultures were examined microscopically and spectrometrically.

Structural Characterization

Capillary Zone Electrophoresis Peptide purity was ascertained by capillary zone electrophoresis. Analysis was performed on a model 270-HT capillary electrophoresis system (PE Applied Biosystems). Two nl of the sample were injected using vacuum to a 50 µm × 72-cm fused silica capillary and run in 20 mM citrate buffer at pH 2.5 under 20 kV from anode to cathode at 30 °C for 20 min. Migration was monitored at 200 nm.

Microsequence Analysis Automated Edman degradation of the native and pyridylethylated peptides and detection of phenylthiohydantoin derivatives were performed on a pulse liquid automatic sequenator (PE Applied Biosystems, model 473A).

Reduction and S-Pyridylethylation One nmol of purified peptide was submitted to reduction and S-pyridylethylation. The procedure used was reported previously (22).

Matrix-assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS) MALDI-TOF-MS was performed on a Bruker BIFLEXTM (Bremen, Germany) mass spectrometer operating in a positive linear mode as described previously (23).

Enzymatic Digestions

Endoproteinase Lys-C Treatment The pyridylethylated peptide (200 pmol) was treated with endoproteinase Lys-C (Achromobacter protease I; Takara, Otsu, Japan). Digestion was carried out at 37 °C for 6 h in 50 µl of 10 mM Tris-HCl (pH 9) in the presence of 0.01% Tween 20 at a peptide/enzyme ratio of 1:40 (w/w). The reaction was stopped by acidification with 1% trifluoroacetic acid, and the peptide fragments were separated on a narrow bore reversed-phase column (Delta Pak HPIC18, 2 × 150 mm, Waters). Elution was performed with a linear gradient of acetonitrile in acidified water (0.05% trifluoroacetic acid) from 2 to 60% over 80 min at 37 °C at a flow rate of 0.2 ml/min. The fragments were analyzed by MALDI-TOF-MS, and the enzymatically derived fragment corresponding to the C terminus of the protein was sequenced by Edman degradation.

Determination of the Cysteine Arrangement by Thermolysin Digestion Eight µg of the native peptide were treated with thermolysin at a peptide/enzyme ratio of 1:2 (w/w) for 1 h in 0.1 M MES buffer at pH 7.4 at 37 °C in presence of 2 mM CaCl2. The digestion was stopped by adding 50 µl of 70% formic acid. The peptide mixture resulting from the enzymatic digestion was subjected to the same reversed-phase HPLC column as above. Elution was performed with a linear gradient of acetonitrile in acidified water from 2 to 50% over 100 min after an isocratic period at 2% acetonitrile during 10 min. The peptides generated by protease treatment were characterized by MALDI-TOF-MS.

Production of Recombinant Peptide

Strains and Media The E. coli strain DH5alpha was used in the cloning procedures, and the S. cerevisiae strain TGY 48-1 was used for expression of recombinant peptide. Yeast cells were transformed using the lithium acetate method (24), and transformed colonies were selected on YNBG medium (0.67% yeast nitrogen base, 1% glucose) supplemented with 0.5% casamino acids, lacking uracil.

Construction of the Synthetic Gene A synthetic gene encoding the 44-amino acid peptide was constructed by ligating three double-stranded oligonucleotide cassettes, preceded by the last five amino acids of the MFalpha 1 proregion, into the HindIII and BamHI sites in the polylinker of pBS/SK+ (Stratagene). For this purpose, the six following oligonucleotides were used: SEA-5 (5'-AGCTTGGATAAAAGAGACAAGTTGATTGGCAGCTGTGTTTGGGGCGCCGTCA-3'), SEA-6 (5'-ACTACACTAGTGACTGCAACGGCGAGTGCAAGCGCCGCGGTTACAAGGGTGG-3'), SEA-7 (5'-CCATTGTGGATCCTTCGCTAACGTTAACTGTTGGTGTGAAACCTGATAGGTCGACA-3'), SEA-8 (5'-GATCTGTCGACCTATCAGGTTTCACACCAACAGTTAACGTTAGCGAAGGATC-3'), SEA-9 (5'-CACAATGGCCACCCTTGTAACCGCGGCGCTTGCACTCGCCGTTGCAGTCACT-3'), and SEA-10 (5'-AGTGTAGTTGACGGCGCCCCAAACACAGCTGCCAATCAACTTGTCTCTTTTATCCA-3').

Sites for restriction enzymes, which do not alter the coding sequence were incorporated into the synthetic gene where possible. The HindIII-SalI fragment of the resulting plasmid containing the synthetic gene and the SphI-HindIII fragment of M13JM132 containing the MFalpha 1 promoter and the preprosequence were subcloned into the SphI and SalI sites of JM138 to create the vector pSEA1. The SphI-SalI fragment of pSEA1 containing the full expression cassette for peptide production in yeast was then cloned into the yeast shuttle vector pTG4812 to give the expression plasmid pSEA2 (for more details, see Ref. 25). The plasmids were all controlled by sequencing.

Large Scale Production and Purification of Recombinant Peptide S. cerevisiae strain TGY 48-1 was transformed with the expression plasmid pSEA2, and transformants were selected by growth at 29 °C on YNBG medium supplemented with casamino acids lacking uracil. For large scale peptide preparation, the culture medium was inoculated at a dilution of 1:50 with a 48-h preculture of the selected transformant, and an additional 48-h growth was performed at 29 °C. Yeast were harvested by centrifugation at 4000 rpm for 30 min at 4 °C. The supernatant was carefully decanted, and the pellet was discarded as the recombinant peptide was secreted from the cells. The supernatant was subjected to solid-phase extraction on an open column filled with C18 reversed phase (preparative C18, 125 Å, Waters; 48 g of phase/4 liters of supernatant), solvated with methanol, and further equilibrated with acidified water. Elution was performed with 40% acetonitrile in acidified water and lyophilized under vacuum, reconstituted in MilliQ water (Millipore Corp.), and applied on a cation column (Aquapore cation, 20 µm, 250 × 10 mm, Brownlee) equilibrated in 25 mM ammonium acetate buffer at pH 3.6. Elution was performed with a linear gradient of 0-100% 1 M NaCl in ammonium acetate buffer over 30 min at a flow rate of 2 ml/min. During the purification step, the column effluent was monitored by absorbance at 225 nm. The collected fraction containing the peptide was desalted on a reversed-phase column (Aquapore preparative C18, 250 × 10 mm, Brownlee) equilibrated with 2% acetonitrile in acidified water. Elution was performed with a linear biphasic gradient of acetonitrile in acidified water from 2 to 20% over 10 min and from 20 to 40% over 30 min at a flow rate of 3 ml/min. The fraction containing the peptide was lyophilized and kept as dry powder.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Isolation of the Antibacterial and Antifungal Peptides from Bacteria-challenged Insects-- One hundred fifth instar larvae of H. virescens were challenged by injection of bacteria, and their hemolymph (2 ml) was collected after 24 h. In parallel, 2 ml of hemolymph from unchallenged larvae were treated under the same conditions. The hemocytes were removed by centrifugation, and the antimicrobial peptides were extracted from the cell-free hemolymph in acidic condition during 30 min in an ice-cold water bath under gentle shaking. The acidic extracts were then submitted to prepurification by solid phase extraction onto Sep-Pak C18 cartridges. Elution was sequentially performed with 10, 40, and 100% acetonitrile in acidified water. After concentration, the various fractions obtained from both acidic extracts were tested for their antimicrobial activity by liquid growth inhibition assays against M. luteus, E. coli 363, and N. crassa. Only the 40% Sep-Pak fractions were found to contain antimicrobial activity and were further applied on an Aquapore RP-300 C8 column. Elution was performed with a linear gradient of acetonitrile, and aliquots of the eluted fractions were tested for their antimicrobial activity by liquid growth inhibition assays against the three test organisms. Several fractions from immune larvae were found to contain strong antifungal and/or antibacterial activity (Fig. 1); in contrast, weak activities were detected in the control experiment (data not shown). Here we have focused on the purification of the compound present in fraction A eluted at 28% acetonitrile in acidified water, which exhibited the strongest antifungal activity. The active molecule was further purified by a two-step purification procedure (see "Materials and Methods"). Pure antifungal compound was obtained, as judged by capillary zone electrophoresis (data not shown). MALDI-TOF-MS gave a single molecular mass at 4784.8 Da, confirming the purity of the antifungal molecule (data not shown).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   First reversed-phase HPLC separation of immune hemolymph of H. virescens. The 40% acetonitrile fraction obtained after prepurification by solid phase extraction was analyzed on an Aquapore RP-300 C8 column. Elution was performed with a linear gradient (dotted line) of acetonitrile in acidified water. Absorbance was monitored at 225 nm (solid line). Antimicrobial activities were detected by liquid growth inhibition assays against M. luteus, (white column), E. coli (dotted column), and N. crassa (black column). The inset shows the final purification of fraction A, which contains the active antifungal compound.

Characterization of the Isolated Antifungal Peptide-- One nmol of purified antifungal peptide was subjected to reduction and S-pyridylethylation and subsequently to MALDI-TOF-MS measurement. The obtained molecular mass at 5422.3 Da, in excess of 637.5 Da to the mass measured on the native molecule, corresponds to six pyridylethylated groups, suggesting the presence of six cysteine residues. One hundred pmol of the S-pyridylethylated peptide were then submitted to Edman degradation, and a partial 41-residue NH2-terminal amino acid sequence was obtained (Fig. 2). The mass calculated for this N-terminal sequence is lower by 333.4 Da than the measured molecular mass of the native peptide at 5422.3 Da. This clearly establishes that the sequence obtained by Edman degradation is only a partial sequence. To obtain the full sequence, we used endoproteinase Lys-C to cleave the pyridylethylated peptide after the Lys residues at positions 2, 23, and 28 under the conditions described under "Materials and Methods." The digest was analyzed by reversed-phase HPLC (data not shown), and the peptide fragments were measured for their respective molecular masses by MALDI-TOF-MS. Five major peaks (2661.7, 2001.2, 2779.3, 2535.7, and 5422.5 in MH+) were obtained. The peak at 5422.5 MH+ (mass/charge) corresponds to the native molecule, while the peptide fragments yielding the molecular masses at 2778.3 and 2534.7 Da correspond to the predicted fragments from the N-terminal sequence. Only the fragments at 2661.7 and 2001.2 MH+ did not fit with any possible cleavage product, suggesting that both include the C-terminal end. The mass difference of 659.5 Da between these two fragments can be explained by the presence of the additional sequence Arg-Arg-Gly-Tyr-Lys (residues 24-28) in the N-terminal part of the 2661.7 MH+ fragment obtained by Edman degradation of the native peptide. To obtain the C-terminal sequence information, the shortest fragment was subjected to Edman degradation and the following sequence was obtained: Gly-Gly-His-Cys*-Gly-Ser-Phe-Ala-Asn-Val-Asn-Cys*-Trp-Cys*-Glu-Thr, where Cys* represents a pyridylethylated cysteine residue. The calculated mass of the sequence is in perfect agreement with the molecular mass of 2000.2 Da measured by MALDI-TOF-MS, establishing that there is no C-terminal amidation. The overlap observed with the N-terminal sequence confirmed the identity of this fragment as the C-terminal part of this 44-amino acid antifungal peptide. The full sequence of the molecule is shown in Fig. 2. The comparison between the calculated mass after Edman degradation (4791.3 Da) and the measured mass by MALDI-TOF-MS (4784.8 Da) indicates that the six cysteine residues are engaged in the formation of three intramolecular disulfide bonds. The data bank analysis (BLAST program in the data base Swiss-Prot; Ref. 26) showed that the peptide has significant sequence similarities with the Drosophila antifungal peptide drosomycin and insect defensins. Therefore, we assumed that the cysteine arrangement is identical to that of insect defensins (Cys(1)-Cys(4), Cys(2)-Cys(5), and Cys(3)-Cys(6)) (27), which is also conserved in the core of drosomycin (Cys(2)-Cys(5), Cys(3)-Cys(6), and Cys(4)-Cys(7)) (25). The disulfide array of the peptide was determined by thermolysin digestion, separation of the peptidic fragments by HPLC, and measurement of their respective molecular mass by MALDI-TOF-MS. The major peak (peak 6 in Fig. 3) had a molecular mass of 4784.4 Da, corresponding to the native molecule. Four minor peaks (peaks 1-4 in Fig. 3) corresponding to the digest products yielded single molecular masses at 1184.2, 2192.9, 2355.7, and 2337.7 Da. Peak 1 yielded a molecular mass at 1184.2 Da, which is in agreement with the peptidic fragment Ile4-Cys7 linked to the fragment Tyr27-Ser34 through an intramolecular disulfide bridge between Cys7 and Cys32 (see inset in Fig. 3). The mass of peak 4 can be explained by admitting the connection of the fragment Tyr14-Gly26 to the fragment Val38-Thr44. This indicates that the disulfide bonds are Cys18-Cys40 and Cys22-Cys42. The mass difference between peaks 2 and 3 of 162.8 Da corresponds to a Tyr residue, and the masses obtained by MALDI-TOF-MS are in perfect agreement with the digestion products proposed in Fig. 3. Taken together, the data are compatible with the following disulfide array: Cys7(1)-Cys32(4), Cys18(2)-Cys40(5), and Cys22(3)-Cys42(6), which is identical to that determined for insect defensins and to the three internal disulfide bridges of drosomycin.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   Amino acid sequence of the H. virescens antifungal peptide. After sequencing of 100 pmol of S-pyridylethylated peptide by Edman degradation, a partial sequence was obtained. To get full sequence information, an endoproteinase Lys-C treatment was performed, and the masses of the peptidic fragments were obtained by MALDI-TOF-MS are shown in MH+. Sequencing of the 2001.2 MH+ fragment allowed full sequence information.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Reversed-phase HPLC of the H. virescens antifungal peptide treated with thermolysin. After digestion by thermolysin, the native antifungal peptide was loaded onto a narrow bore reversed-phase column. Elution was performed with a linear gradient of acetonitrile in acidified water (dotted line), and absorbance was monitored at 225 nm (solid line). MALDI-TOF-MS was performed on peaks 1-6. The m/z values obtained for peaks 1-4 and the deduced sequences are indicated as well as the linkage between the cysteine residues.

Recombinant Synthesis of the H. virescensAntifungal Peptide and Analysis of Its Activity Spectrum-- In order to produce sufficient amounts of the peptide for detailed studies on its activity spectrum, we expressed a synthetic cDNA in the yeast S. cerevisiae. The synthetic gene was constructed by annealing and ligating six individual oligonucleotides to form a double-stranded oligonucleotide cassette. This cassette is preceded by the last five amino acids of the yeast mating factor MFalpha 1 proregion to generate a HindIII site necessary for an in-frame fusion with the preprosequence, responsible for secretion of the peptide by the yeast strain. The MFalpha 1 promoter directs the expression of the gene, and Kex2 endopeptidase cleaves the fusion protein after the dipeptide site Lys-Arg at the C terminus of the MFalpha 1 promoter. The full expression block for peptide production was cloned into pTG4812 to give the expression plasmid pSEA2, which was used to transform yeast. The 48-h culture was centrifuged, and the cell-free supernatant was subjected to solid-phase extraction. The fraction eluted with 40% acetonitrile was applied on a cation exchange column, and the fraction containing the peptide was desalted by reversed-phase HPLC and lyophilized. With this system, the average recovery of pure peptide was 2.5 mg/1 liter of culture medium. MALDI-TOF-MS showed that the recombinant peptide exhibits the same molecular mass as the native molecule, and capillary zone electrophoresis analysis confirmed its purity. The antifungal activity of recombinant and native peptide were compared by measuring their MIC on N. crassa and found to be identical for both molecules. The purified recombinant peptide was tested on a variety of bacterial and fungal strains. No antibacterial activity against 15 Gram-positive and 10 Gram-negative bacterial strains was detected even at concentrations of up to 50 µM. However, in marked contrast, the H. virescens antifungal peptide showed a strong antifungal activity against six fungal strains tested (Table I). In liquid growth inhibition assays, the pure recombinant peptide had marked activity against N. crassa (MIC = 0.1-0.2 µM), F. culmorum (MIC = 0.2-0.4 µM), and N. hematococca (MIC = 0.4-0.8 µM). The peptide was also found to be active against F. oxysporum (MIC = 1.5-3 µM), T. viride (MIC = 1.5-3 µM), and A. fumigatus (MIC = 6-12 µM). Furthermore, it showed a strong activity against two of the four yeast strains tested: C. albicans and C. neoformans at a MIC of 2.5-5 µM. The peptide was inactive against C. glabrata, up to 50 µM, and against S. cerevisiae, even at a concentration as high as 100 µM. The antifungal activity was tested in a similar assay on N. crassa at physiologic ionic strength (137 mM NaCl), and the MIC recorded for the peptide was identical to that of the classical tests, suggesting that the activity of the peptide is not affected by salts. In contrast, an activity reduction (4-fold) was observed for drosomycin in the presence of salts (data not shown). Finally, spores of the fungus N. crassa were incubated in the presence of various concentrations of the peptide (0.04-20 µM). After 48 h, the medium containing the peptide was replaced by fresh medium, and 2 days later no growth recovery had occurred when the peptide concentration during the initial incubation was 0.15 µM or higher. This result demonstrates that the peptide is fungicidal at this concentration. We propose the name of heliomicin for this novel antifungal peptide from H. virescens.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Antimicrobial activity spectrum of recombinant heliomicin compared to Phormia defensin and drosomycin from Drosophila
The MIC is expressed in µM as a final concentration. Several dilutions (50-0.1 µM) of the antimicrobial peptides were tested using the liquid growth inhibition assay to determine MIC.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The data presented in this report establish that the larval hemolymph of a lepidopteran species, H. virescens, contains a strongly inducible cysteine-rich antifungal peptide. The molecule was purified to homogeneity and fully characterized at the level of its amino acid sequence by a combination of reversed-phase chromatography, capillary zone electrophoresis, Edman degradation, protease digestion, and MALDI-TOF-MS. The peptide, which was named heliomicin, consists of 44 residues and contains six cysteines engaged in three intramolecular disulfide bridges. Cysteine-containing antimicrobial peptides had so far not been reported from lepidopteran insects, although this order served for the first successful identification of antimicrobial peptides and namely the discovery of cecropins and attacins by Boman and associates (5, 13). Similarly, inducible antifungal activities had not yet been recorded in Lepidoptera.

Sequence comparison with the group of insect defensins shows that the Heliothis antifungal molecule presents the same cysteine arrangement (Cys(1)-Cys(4), Cys(2)-Cys(5), and Cys(3)-Cys(6)) as that present in these antibacterial peptides (22, 28) (Fig. 4). In addition to the six cysteines, the residues strictly conserved between heliomicin and insect defensins are three glycines at equivalent positions (numbered 26, 29, and 30 in heliomicin). The sequence of heliomicin is also evocative of that of antifungal peptides recently reported from Drosophila (drosomycin; Ref. 25) and plants (e.g. Rs-AFP1 from Raphanus sativus; Ref. 29) (Fig. 4). In particular, heliomicin shares the cysteine array with these molecules. Note that drosomycin and Rs-AFP1 have in addition two external cysteines absent from defensins. Drosomycin and heliomicin also present a conserved cluster of four amino acids (Cys-Trp-Cys-Glu) located on the third beta -strand at the C-terminal part of drosomycin (30). They also have in common the hydrophobic dipeptide Ala-Val at positions 11 and 12; three glycine residues at positions 5, 26, and 30; and a lysine at position 23 (numbering relative to heliomicin). As regards plant defensins, the residues conserved between heliomicin and Rs-AFP1 are restricted to the six cysteine residues and to two glycines at positions 5 and 30 (relative to heliomicin, as shown in Fig. 4).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Sequence comparison of heliomicin with other antimicrobial peptides from insects and plants. Heliomicin was compared (i) to two antifungal peptides (drosomycin from D. melanogaster and Rs-AFP1 from the Brassicaceae R. sativus) and (ii) to some of the most representative insect defensins. Identical amino acids and conservative replacements are shown in gray boxes. Bars indicate gaps to optimize the alignments.

Heliomicin presents the structural motif CSalpha beta . In this scaffold, an invariant Cys-(Xaa)3-Cys sequence of an alpha -helix is linked to an Cys-Xaa-Cys sequence of a beta -sheet. A similar motif named CSH (for cysteine-stabilized helix) was initially described on the basis of NMR studies by Tamaoki et al. in endothelin (31). This motif appears now to be commonly shared by a variety of antibiotics and toxins like short- and long-chain scorpion toxins (32), insect defensins (first report in Phormia defensin; Ref. 33), the Drosophila drosomycin (30), plant defensins (e.g. Rs-AFP1; Ref. 34), and gamma -thionins (35). The three-dimensional structure has been established by NMR for some of these defense molecules, and we can anticipate that the lepidopteran peptide will adopt a similar conformation.

In order to obtain sufficient amounts of heliomicin for three-dimensional structure determination by two-dimensional NMR and for detailed studies on its activity spectrum, we have successfully expressed a synthetic gene in the eukaryote S. cerevisiae. The purified recombinant molecule exhibits the same characteristics as the native molecule and was used to establish the activity spectrum of the peptide. Heliomicin was found to be active against various fungal and yeast strains, but it had no activity against either Gram-positive or Gram-negative bacterial strains even at concentration as high as 50 µM, which corresponds roughly to 10 times the estimated concentration of heliomicin in immune challenged H. virescens larvae (Table I). We noted that heliomicin is active against most of the filamentous fungi tested at concentrations significantly lower than those of the Drosophila antifungal peptide drosomycin. Furthermore, the latter exhibits no antifungal activity against the yeast strains C. albicans and C. neoformans. Note that Phormia defensin exhibits also some activity against several fungi, but at concentrations >= 4 times higher than heliomicin. At physiological ionic strength, heliomicin exhibits the same activity as in the classical tests against the filamentous fungus N. crassa. This contrasts with the reduction of antimicrobial activity observed in the presence of salts for other antimicrobial peptides such as drosomycin, human beta -defensins 1 and 2 (36), and lebocins (37). This indicates that the antifungal activity of heliomicin is not based on charge differences but may involve other mechanisms such as interactions with a receptor in the target organism.

In conclusion, septic injury in H. virescens results in the production of an antifungal peptide, heliomicin. Sequence comparison indicates that heliomicin is related to insect defensins and may represent the insect defensin prototype of Lepidoptera. However, the antifungal activity observed for the Heliothis peptide prompts us to classify heliomicin in the group of antifungal peptides such as plant defensins and drosomycin.

    ACKNOWLEDGEMENT

We are grateful to Martine Schneider for capillary electrophoresis analysis.

    FOOTNOTES

* This work was supported by CNRS, the University Louis Pasteur of Strasbourg, and Rhône-Poulenc Agro. The peptide was patented April 15, 1998 under the number FR9804933.

The protein sequence reported in this paper has been submitted to the Swiss-Prot protein data bank with the accession number P81544.

To whom correspondence should be addressed. Tel.: 33388417062; Fax: 33388606922; E-mail: bulet{at}ibmc.u-strasbg.fr.

    ABBREVIATIONS

The abbreviations used are: HPLC, high pressure liquid chromatography; MIC, minimal inhibitory concentration; MALDI-TOF-MS, matrix-assisted laser/desorption time of flight mass spectrometry; MES, 4-morpholineethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Oerke, E.-C., Dehne, H.-W., Schönbeck, F., and Weber, A. (1994) Crop Production and Crop Protection, Elsevier, Amsterdam
  2. Hoffmann, J. A., and Reichhart, J.-M. (1997) Trends Cell Biol. 7, 309-316[CrossRef]
  3. Hetru, C., Hoffmann, D., and Bulet, P. (1998) in Molecular Mechanisms of Immune Response in Insects (Brey, P. T., and Hultmark, D., eds), pp. 40-66, Chapman and Hall, London
  4. Hoffmann, J. A., Reichhart, J.-M., and Hetru, C. (1996) Curr. Opin. Immunol. 8, 8-13[CrossRef][Medline] [Order article via Infotrieve]
  5. Steiner, H., Hultmark, D., Engström, A., Bennich, H., and Boman, H. G. (1981) Nature 292, 246-248[Medline] [Order article via Infotrieve]
  6. Boman, H. G. (1995) Annu. Rev. Immunol. 13, 61-92[CrossRef][Medline] [Order article via Infotrieve]
  7. Cociancich, S., Ghazi, A., Hetru, C., Hoffmann, J. A., and Letellier, L. (1993) J. Biol. Chem. 268, 19239-19245[Abstract/Free Full Text]
  8. Ehret-Sabatier, L., Loew, D., Goyffon, M., Fehlbaum, P., Hoffmann, J. A., van Dorsselaer, A., and Bulet, P. (1996) J. Biol. Chem. 271, 29537-29544[Abstract/Free Full Text]
  9. Charlet, M., Chernysh, S., Philippe, H., Hetru, C., Hoffmann, J. A., and Bulet, P. (1996) J. Biol. Chem. 271, 21808-21813[Abstract/Free Full Text]
  10. Fehlbaum, P., Bulet, P., Michaut, L., Lagueux, M., Broekaert, W. F., Hetru, C., and Hoffmann, J. A. (1994) J. Biol. Chem. 269, 33159-33163[Abstract/Free Full Text]
  11. Fehlbaum, P., Bulet, P., Chernysh, S., Briand, J. P., Roussel, J. P., Letellier, L., Hetru, C., and Hoffmann, J. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 1221-1225[Abstract/Free Full Text]
  12. Bulet, P., Dimarcq, J.-L., Hetru, C., Lagueux, M., Charlet, M., Hegy, G., van Dorsselaer, A., and Hoffmann, J. A. (1993) J. Biol. Chem. 268, 14893-14897[Abstract/Free Full Text]
  13. Hultmark, D., Engström, A., Bennich, H., Boman, H. G., Andersson, K., and Steiner, H. (1983) EMBO J. 2, 571-576[Medline] [Order article via Infotrieve]
  14. Kanai, A., and Natori, S. (1990) Mol. Cell Biol. 10, 6114-6122[Medline] [Order article via Infotrieve]
  15. Dimarcq, J. L., Keppi, E., Dunbar, B., Lambert, J., Reichhart, J.-M., Hoffmann, D., Rankine, S. M., Fothergill, J. E., and Hoffmann, J. A. (1988) Eur. J. Biochem. 171, 17-22[Abstract]
  16. Bulet, P., Hegy, G., Lambert, J., Van Dorsselaer, A., Hoffmann, J. A., and Hetru, C. (1995) Biochemistry 34, 7394-7400[Medline] [Order article via Infotrieve]
  17. Axen, A., Carlsson, A., Engström, A., and Bennich, H. (1997) Eur. J. Biochem. 247, 614-619[Abstract]
  18. Hara, S., and Yamakawa, M. (1995) J. Biol. Chem. 270, 29923-29927[Abstract/Free Full Text]
  19. Hara, S., and Yamakawa, M. (1995) Biochem. J. 310, 651-656[Medline] [Order article via Infotrieve]
  20. Ourth, D. D., Lockey, T. D., and Renis, H. E. (1994) Biochem. Biophys. Res. Commun. 200, 35-44[CrossRef][Medline] [Order article via Infotrieve]
  21. Lockey, T. D., and Ourth, D. D. (1996) Eur. J. Biochem. 236, 263-271[Abstract]
  22. Bulet, P., Cociancich, S., Reuland, M., Sauber, F., Bischoff, R., Hegy, G., Van Dorsselaer, A., Hetru, C., and Hoffmann, J. A. (1992) Eur. J. Biochem. 209, 977-984[Abstract]
  23. Uttenweiler-Joseph, S., Moniatte, M., Lambert, J., Van Dorsselaer, A., and Bulet, P. (1997) Anal. Biochem. 247, 366-375[CrossRef][Medline] [Order article via Infotrieve]
  24. Ito, H., Fukuda, Y., Murata, K., and Kimura, K. (1983) J. Bacteriol. 153, 163-168[Medline] [Order article via Infotrieve]
  25. Michaut, L., Fehlbaum, P., Moniatte, M., Van Dorsselaer, A., Reichhart, J.-M., and Bulet, P. (1996) FEBS Lett. 395, 6-10[CrossRef][Medline] [Order article via Infotrieve]
  26. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990) J. Biol. Mol. 215, 403-410[CrossRef]
  27. Hoffmann, J. A., and Hetru, C. (1992) Immunol. Today 13, 411-415[CrossRef][Medline] [Order article via Infotrieve]
  28. Lambert, J., Keppi, E., Dimarcq, J. L., Wicker, C., Reichhart, J. M., Dunbar, M., Lepage, P., Van Dorsselaer, A., Hoffmann, J. A., Fothergill, J., and Hoffmann, J. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 262-266[Abstract]
  29. Terras, F. R. G., Schoofs, H. M. E., De Bolle, M. F. C., Van Leuven, F., Rees, S. B., Vanderleyden, J., Cammue, B. P. A., and Broekaert, W. F. (1992) J. Biol. Chem. 267, 15301-15309[Abstract/Free Full Text]
  30. Landon, C., Sodano, P., Hetru, C., Hoffmann, J. A., and Ptak, M. (1997) Protein Sci. 6, 1878-1884[Abstract/Free Full Text]
  31. Tamaoki, H., Kobayashi, H., Nishimura, S., Ohkubo, T., Kyogoku, Y., Nakajima, K., Kumagaye, S., Kimura, T., and Sakakibara, S. (1981) Protein Eng. 4, 509-518[Abstract]
  32. Martin-Eauclaire, M. F., and Couraud, F. (1995) Handbook of Neurotoxicity, pp. 683-716, Marcel Dekker, Inc., New York
  33. Cornet, B., Bonmatin, J. M., Hetru, C., Hoffmann, J. A., Ptak, M., and Vovelle, F. (1995) Structure 3, 435-448[Medline] [Order article via Infotrieve]
  34. Fant, F., Vranken, W., Broeckaert, W., and Borremans, F. (1998) J. Mol. Biol. 279, 257-270[CrossRef][Medline] [Order article via Infotrieve]
  35. Bruix, M., Jimenez, M. A., Santoro, J., Gonzales, C., Colilla, F. J., Mendez, E., and Rico, M. (1993) Biochemistry 132, 715-724
  36. Bals, R., Wang, X., Wu, Z., Freeman, T., Bafna, V., Zasloff, M., and Wilson, J. M. (1998) J. Clin. Invest. 102, 874-880[Abstract/Free Full Text]
  37. Hara, S., and Yamakawa, M. (1995) Biochem. J. 310, 651-656[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.